HOME >> BIOLOGY >> NEWS
Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms

HORSHAM, PA (April 3, 2000) -- Exisulind (Aptosyn™) and other selective apoptotic antineoplastic drugs (SAANDs) inhibit the growth of prostate cancer cells in two ways, said researchers from Columbia University and their collaborators at Cell Pathways, Inc. (Nasdaq: CLPA). First, they directly kill cancerous prostate cells by inducing apoptosis. Secondly, they decrease expression of the androgen receptor in the cancerous prostate cells, making them less responsive to the growth-promoting effects of androgens in their environment. The Columbia University scientists and their Cell Pathways' collaborators presented their preclinical findings on Sunday April 2, 2000 at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco.

The researchers also demonstrated in a prostate cancer cell line that exisulind (Aptosyn™) and two other SAANDs, CP461 and CP248, inhibited the cellular expression and secretion of prostate specific antigen (PSA) at the same concentrations that induced apoptosis in the cells.

Dr. Bernard Weinstein, the senior investigator of these studies and director of the Columbia University Comprehensive Cancer Center, emphasized that "because of their dual mechanism of action, these agents are also effective in prostate cancer cells that have become independent of androgens."

"These findings also support the usefulness of PSA assays for measuring the efficacy of SAANDs in clinical trials for prostate cancer therapy or chemoprevention, as they demonstrate that a reduction in PSA levels accurately reflects cell death and not merely a reduction in PSA production when these drugs are used," added Rifat Pamukcu, M.D., chief scientific officer and senior vice president of research at Cell Pathways, Inc.

"This laboratory research complements the findings of our clinical trial of exisulind (Aptosyn™) as a treatment for post-prostatectomy men at risk of prostate cancer recurre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2 3

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. New hydrothermal vents discovered as South Pacific Odyssey research begins
3. Posters highlight water, energy and other natural resource research
4. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
5. K-State, other universities to study how climate affects plant evolution
6. The search for a kinder, gentler chemotherapy
7. Green tea research leads to gum and other products
8. New survey reveals insights into unique relationship between mothers and pediatricians
9. Manatee population rising in some regions, likely stalled or declining in others
10. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
11. Another key for the p53 door

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... ... January 20, 2017 , ... ... announced today the next evolution in spinal fusion, the MISquito Percutaneous Pedicle ... to the competition, SpineFrontier is focused on technique driven product solutions that ...
(Date:1/19/2017)... LOUISVILLE, Ky. and HOUSTON ... Prenatal Inc. ("NX Prenatal") today announced the formation ... brings together leading clinicians and industry veterans who ... the company as it accelerates development of its ... positioned to provide medical, clinical and strategic guidance ...
(Date:1/19/2017)... Switzerland (PRWEB) , ... January ... ... provider of advanced software solutions for pharmaceutical research and development (R&D), today ... expertise in omic data analysis and interpretation for the rapidly evolving field ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
Breaking Biology Technology:
Cached News: